IL22 and inflammatory bowel disease: Interestingly, SCFAs also promote human CD4+ T cell IL-22 production, even from IBD patients, our study provides SCFAs as a new potential therapeutic target for suppressing intestine infection and inflammation, and eventually treatment of IBD patients.